Literature DB >> 2386376

Protein binding of vancomycin in a patient with immunoglobulin A myeloma.

T G Cantú1, J D Dick, D E Elliott, R L Humphrey, D M Kornhauser.   

Abstract

Atypical vancomycin pharmacokinetics were observed in an immunoglobulin A myeloma patient. Drug concentrations in serum were extremely elevated, the elimination half-life was prolonged despite normal renal function, and the vancomycin therapy was ineffective. Extensive binding of vancomycin, presumably by high concentrations of an aberrant immunoglobulin A protein, may have accounted for these observations.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2386376      PMCID： PMC176003          DOI： 10.1128/AAC.34.7.1459

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  22 in total

1.  Renal excretion of vancomycinin in kidney disease.

Authors:  H E Nielsen; H E Hansen; B Korsager; P E Skov
Journal:  Acta Med Scand       Date:  1975-04

Review 2.  The clinical relevance of protein binding and tissue concentrations in antimicrobial therapy.

Authors:  R Wise
Journal:  Clin Pharmacokinet       Date:  1986 Nov-Dec       Impact factor: 6.447

3.  The relevance of pharmacokinetics to in-vitro models: protein binding--does it matter?

Authors:  R Wise
Journal:  J Antimicrob Chemother       Date:  1985-01       Impact factor: 5.790

4.  Binding of teicoplanin to human serum albumin.

Authors:  A Assandri; A Bernareggi
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

5.  Evaluation of an automated fluorescence polarization immunoassay for vancomycin.

Authors:  B H Filburn; V H Shull; Y M Tempera; J D Dick
Journal:  Antimicrob Agents Chemother       Date:  1983-08       Impact factor: 5.191

6.  The influence of protein binding upon tissue fluid levels of six beta-lactam antibiotics.

Authors:  R Wise; A P Gillett; B Cadge; S R Durham; S Baker
Journal:  J Infect Dis       Date:  1980-07       Impact factor: 5.226

7.  Vancomycin serum protein binding determination by ultrafiltration.

Authors:  B H Ackerman; E H Taylor; K M Olsen; W Abdel-Malak; A A Pappas
Journal:  Drug Intell Clin Pharm       Date:  1988-04

8.  Effect of protein binding on antibiotic activity in vivo.

Authors:  D J Merrikin; J Briant; G N Rolinson
Journal:  J Antimicrob Chemother       Date:  1983-03       Impact factor: 5.790

9.  The influence of serum albumin and alpha 1-acid glycoprotein on vancomycin protein binding in patients with burn injuries.

Authors:  H Z Zokufa; L D Solem; K A Rodvold; K B Crossley; J H Fischer; J C Rotschafer
Journal:  J Burn Care Rehabil       Date:  1989 Sep-Oct

10.  Early termination of a prospective, randomized trial comparing teicoplanin and flucloxacillin for treating severe staphylococcal infections.

Authors:  P Calain; K H Krause; P Vaudaux; R Auckenthaler; D Lew; F Waldvogel; B Hirschel
Journal:  J Infect Dis       Date:  1987-02       Impact factor: 5.226
View more
  7 in total

1.  Prospective Cohort Study of the Tolerability of Prosthetic Joint Infection Empirical Antimicrobial Therapy.

Authors:  Claire Triffault-Fillit; Florent Valour; Ronan Guillo; Michel Tod; Sylvain Goutelle; Sébastien Lustig; Michel-Henry Fessy; Christian Chidiac; Tristan Ferry
Journal:  Antimicrob Agents Chemother       Date:  2018-09-24       Impact factor: 5.191

2.  Refining vancomycin protein binding estimates: identification of clinical factors that influence protein binding.

Authors:  Jill M Butterfield; Nimish Patel; Manjunath P Pai; Thomas G Rosano; George L Drusano; Thomas P Lodise
Journal:  Antimicrob Agents Chemother       Date:  2011-06-13       Impact factor: 5.191

3.  Characteristics of ceftriaxone binding to immunoglobulin G and potential clinical significance.

Authors:  H Sun; M S Chow; E G Maderazo
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

4.  Factors impacting unbound vancomycin concentrations in different patient populations.

Authors:  Matthijs Oyaert; Isabel Spriet; Karel Allegaert; Anne Smits; Kim Vanstraelen; Nele Peersman; Joost Wauters; Jan Verhaegen; Pieter Vermeersch; Steven Pauwels
Journal:  Antimicrob Agents Chemother       Date:  2015-09-08       Impact factor: 5.191

5.  Serum protein-binding characteristics of vancomycin.

Authors:  H Sun; E G Maderazo; A R Krusell
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191

6.  Prediction of Unbound Vancomycin Levels in Intensive Care Unit and Nonintensive Care Unit Patients: Total Bilirubin May Play an Important Role.

Authors:  Xiao Li; Wen Xu; Ran Li; Qie Guo; Xiangpeng Li; Jialin Sun; Shuhong Sun; Jing Li
Journal:  Infect Drug Resist       Date:  2021-07-02       Impact factor: 4.003

Review 7.  Review on Usage of Vancomycin in Livestock and Humans: Maintaining Its Efficacy, Prevention of Resistance and Alternative Therapy.

Authors:  Panditharathnalage Nishantha Kumara Wijesekara; Wikum Widuranga Kumbukgolla; Jayaweera Arachchige Asela Sampath Jayaweera; Diwan Rawat
Journal:  Vet Sci       Date:  2017-01-26
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.